Canada's Entos Pharmaceuticals plots $137M R&D, manufacturing hub in Edmonton
The facility will be used to develop and produce Entos' Fusogenix proteolipid vehicles (PLVs), which attracted Eli Lilly's interest for a partnership. The governments of Canada and Alberta are chipping in to help fund the site.
The facility will be used to develop and produce Entos' Fusogenix proteolipid vehicles (PLVs), which attracted Eli Lilly's interest for a partnership. The governments of Canada and Alberta are chipping in to help fund the site.
